Doggrell Sheila A
Division of Health Practice, Auckland University of Technology-Akoranga Campus, Auckland, New Zealand.
Curr Opin Investig Drugs. 2005 Sep;6(9):962-8.
Biogen Idec, under license from CV Therapeutics, is developing BG-9928, a selective oral adenosine A, receptor antagonist, for the potential treatment of congestive heart failure. By January 2003, phase II trials of BG-9928 were ongoing.
百健艾迪公司（Biogen Idec）获得CV治疗公司的许可，正在研发BG-9928，一种选择性口服腺苷A受体拮抗剂，用于潜在治疗充血性心力衰竭。截至2003年1月，BG-9928的二期试验正在进行中。
